Descripción del proyecto
Herramienta de diagnóstico para detectar la enfermedad de Alzheimer emergente
La enfermedad de Alzheimer (EA) no es curable en sus fases terminales, pero la detección y el tratamiento precoces podría proporcionar unos beneficios importantes desde el punto de vista terapéutico y social. El inicio del tratamiento en las primeras fases podría ralentizar e incluso curar la EA, lo que supondría una reducción drástica de los costes sanitarios. La empresa noruega Pre Diagnostics está trabajando para crear una herramienta de diagnóstico que permita identificar a pacientes en las primeras fases antes de que se haga patente la EA. Esta herramienta de detección de biomarcadores sanguíneos, precisa y rentable, analizará directamente el metabolismo cerebral del paciente y permitirá detectar la disminución de la depuración de amiloide β, que es el primer signo de esta enfermedad. El proyecto financiado con fondos europeos VERDAD ofrecerá apoyo para las etapas reglamentarias finales en el desarrollo de la nueva herramienta y la preparará para su comercialización.
Objetivo
Alzheimer’s Disease (AD) poses an unbearable impact in patients’ life, through progressive loss of cognitive capacities and overall quality of life. In Europe alone, there is currently a €280 bn yearly expenditure related to AD and ~10% of the population above 65 years old is currently affected by the disease, a figure that is expected to triple in the immediate future.
No treatment alternatives are available for AD patients with diagnosed disease and the existing diagnostic tools are very time consuming and expensive (6 months / 10.000 EUR). While AD is not curable at final stages of disease, detection at early stages offer several treatment alternatives for example through counseling and/or dietary interventions.
Detection and treatment of AD in its initial stages could provide major therapeutic and societal benefits. Treatment strategies at early stages could either slow down or even cure AD which would dramatically reduce the health care costs.
PreDiagnostics will exploit and transfer research knowledge developed by its founders to a commercial setting and provide a diagnostic tool to identify patients at early stages before disease is evident. Through the VERDAD project, PreDiagnostics will finalize the final regulatory steps and introduce into the market a novel, accurate and cost-effective blood biomarker detection tool. This tool directly analyses the patients’ brain metabolism and detects reduced clearance of beta-amyloid which is the first step in AD pathology.
The VERDAD project will allow for market introduction of a disruptive diagnostic test to identify AD decades before clinical signs are visible. This will facilitate early disease diagnosis and implementation of prevention strategies in likely patients. We have developed necessary collaborations to roll-out our diagnostic tool which will lead to major costs saving for the Health Care sector, generate new employment opportunities and in unlock a revenue stream of over €1.5bn 10-years post-Project.
Ámbito científico
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-2
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
0382 Oslo
Noruega
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.